This application for re-selection as a Diabetes TrialNet Clinical Center consists of a leadership statement outlining our perspective and approach to address TrialNet's current challenges. It also describes our Clinical Center's current and planned activities to accomplish TrialNet's mission including innovative approaches to collaboratively and efficiently achieving our overarching goal - delaying and preventing the onset of clinical type 1 diabetes. The TrialNet Northwest Clinical Center recruitment region encompasses Alaska, Washington, Oregon, Idaho, and Montana. We work with more than a dozen Affiliate sites, local and regional T1D advocacy groups and diabetes health care providers to assure that those with T1D are aware that their relatives are at risk for disease and that screening along with the possibility of prevention trials through TrialNet are available. We also have significant recruitment efforts using digital media, including the use of websites, Facebook, Twitter, to convey information and foster discussion. More than 7500 individuals in our region have been screened for risk. TrialNet Northwest Clinical Center team members are active participants and are in leadership roles in the TrialNet network. We plan to work collaboratively within the new TrialNet structure to prevent or delay type 1 diabetes.

Public Health Relevance

TrialNet is an international network with the primary aim of delaying or preventing type 1 diabetes. This is an application from Dr. Greenbaum and the Benaroya Research Institute to continue as the Type 1 Diabetes TrialNet Northwest Clinical Center and conduct clinical trials to stop type 1 diabetes. Our recruitment region encompasses Alaska, Washington, Oregon, Idaho, and Montana.

Agency
National Institute of Health (NIH)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01DK061034-13
Application #
8776647
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Leschek, Ellen W
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Benaroya Research Institute at Virginia Mason
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98101
Fouts, Alexandra; Pyle, Laura; Yu, Liping et al. (2016) Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects? Diabetes Care 39:1738-44
Narsale, Aditi; Moya, Rosita; Robertson, Hannah Kathryn et al. (2016) Data on correlations between T cell subset frequencies and length of partial remission in type 1 diabetes. Data Brief 8:1348-51
Bundy, Brian N; Krischer, Jeffrey P; Type 1 Diabetes TrialNet Study Group (2016) A model-based approach to sample size estimation in recent onset type 1 diabetes. Diabetes Metab Res Rev 32:827-834
Pugliese, Alberto; Boulware, David; Yu, Liping et al. (2016) HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. Diabetes 65:1109-19
Hao, Wei; Gitelman, Steven; DiMeglio, Linda A et al. (2016) Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care 39:1664-70
Bingley, Polly J; Boulware, David C; Krischer, Jeffrey P et al. (2016) The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia 59:542-9
Moya, Rosita; Robertson, Hannah Kathryn; Payne, Dawson et al. (2016) A pilot study showing associations between frequency of CD4(+) memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes. Clin Immunol 166-167:72-80
Sims, Emily K; Chaudhry, Zunaira; Watkins, Renecia et al. (2016) Elevations in the Fasting Serum Proinsulin-to-C-Peptide Ratio Precede the Onset of Type 1 Diabetes. Diabetes Care 39:1519-26
Cabrera, Susanne M; Wang, Xujing; Chen, Yi-Guang et al. (2016) Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. Eur J Immunol 46:1030-46
Sosenko, Jay M (2016) Staging the progression to type 1 diabetes with prediagnostic markers. Curr Opin Endocrinol Diabetes Obes 23:297-305

Showing the most recent 10 out of 51 publications